Supplementary Figures 1 through 7 and Supplementary Table 1 from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 1. Bioluminescence plots of individual animals following treatment with immune checkpoint blocking mAbs. Supplemental Figure 2. Immune cell infiltrates within intracranial GL261-luc2 tumor following treatment with isotype control IgG or combination therapy with CTLA-4 plus PD-1 mAb therapy. Supplemental Figure 3: Treatment antibody and detection antibody for PD-1 do not share same the epitope. Supplemental Figure 4. Representative immunohistochemistry results of intratumoral CD3+, CD4+ and CD8+ T cell infiltrates following immune checkpoint therapy with mAbs against CTLA-4, PD-1 and both CTLA-4 and PD-1. Supplemental Figure 5. Immune cell infiltration within the draining cervical lymph node (cLN) of GL261-luc2 tumor-bearing mice following treatment with isotype control IgG or combination therapy with mAbs against CTLA-4 plus PD-1. Supplemental Figure 6. Comparisons of chemokine expression levels in sera of mice treated with checkpoint blockade. Supplemental Figure 7: Expression of checkpoint ligands and receptors on GL261-Luc cells in vitro. Supplementary Table 1. Arrangement of chemokines on the Mouse Chemokine Antibody Array.
Authors: David A. Reardon, Prafulla C. Gokhale, Sarah R. Klein, Keith L. Ligon, Scott J. Rodig, Shakti H. Ramkissoon, Kristen L. Jones, Amy Saur Conway, Xiaoyun Liao, Jun Zhou, Patrick Y. Wen, Annick D. Van Den Abbeele, F. Stephen Hodi, Lei Qin, Nancy E. Kohl, Arlene H. Sharpe, Glenn Dranoff, Gordon J. Freeman
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362552191